the co-occurrent disease at an early stage or even pre-clinically (using autoantibodies) is of pivotal importance.
-Bone density is reduced in patients with AIH due to prolonged steroid use and in PBC / PSC due to chronic cholestasis; therefore, osteoporosis management is an important issue in the care of these patients.
-Treatment options should be personalized to address coexisting conditions, especially if overlapping with specific rheumatic or autoimmune diseases.
Abstract.
Autoimmune liver diseases coexist with rheumatic disorders in approximately 30% of cases and may also share pathogenetic mechanisms. Autoimmune liver diseases result from an immunemediated injury of different tissues, with autoimmune hepatitis (AIH) targeting hepatocytes, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) targeting cholangiocytes. Sjögren's syndrome is diagnosed in 7% of AIH cases and serological autoimmunity profiles are a common laboratory abnormality, particularly in the case of serum anti-mitochondrial (PBC) or anti-liver kidney microsomal antibodies (AIH). Therapeutic strategies may overlap between rheumatic and autoimmune liver diseases and practitioners should be vigilant in managing bone loss.
6
(DRB1*0301) and DR7 (DRB1*0701) molecules 26 . It also associates with anti-LKM antibodies 27, 31, 32 . The diagnosis of AIH is defined as definite or probable, based on the Diagnostic Criteria of the International Autoimmune Hepatitis Group (IAIH-G, Table 2 ) 33, 34 . The clinical criteria for the diagnosis are sufficient to establish or rule out a definite or probable AIH in the majority of patients. The revised scoring system was developed as a research tool to ensure the comparability of study populations in clinical trials, and can be used to assess treatment response ( Table 3) , similar to classification criteria utilized in rheumatology 34 . A pretreatment score of 10 points or higher, or a posttreatment score of 12 points or higher, indicate ''probable'' AIH at presentation, with a sensitivity of 100%, a specificity of 73%, and diagnostic accuracy of 67%. A pretreatment score of 15 points, indicative of ''definite AIH'' has a sensitivity of 95%, a specificity of 97%, and a diagnostic accuracy of 94% 35 .
The clinical course of untreated AIH results in significant mortality, with 5-and 10-year survival rates of 50% and 10% respectively. The use of glucocorticoids has dramatically improved the disease course with a 10-year survival rate now exceeding 90% 25 . The complications associated with AIH are similar to those of other progressive liver diseases, as chronic hepatitis can evolve to cirrhosis and ultimately to hepatocellular carcinoma (HCC), despite the use of immunosuppressives.
At the time of diagnosis, approximately 30% of adults have histological evidence of cirrhosis; when appropriately treated, however, only a small number develop cirrhosis during follow-up if biochemical and histology inflammation resolves. The occurrence of HCC in patients with AIH is rare and only develops in long-standing cirrhosis. In the absence of definitive data, primary liver neoplasia incidence is assumed to be similar to other non-viral cases of cirrhosis 25 .
Association with rheumatic diseases
AIH was originally described in association with SLE and currently extrahepatic autoimmune manifestations are found in 20-50% of patients 36 , with the most common being autoimmune thyroiditis, diabetes, rheumatoid arthritis (RA) and ulcerative colitis (UC). Up to 43% of AIH cases will have a family history of autoimmune diseases, in particular thyroid diseases and type 1 diabetes 7 37 . The occurrence of other autoimmune diseases in AIH is included in the original and revised International Autoimmune Hepatitis Scoring System (Table 3) 33 . Concurrent autoimmune disorders tend to cluster in women with AIH type 1, particularly if positive for the human leukocyte antigen (HLA)-DR4 38 . Moreover, elderly patients with AIH have higher frequency of concurrent rheumatic conditions than young adults 39 . SjS has been reported in up to 7% of AIH patients, while RA in 2-4%. Though liver dysfunction has been reported in up to 60% of SLE patients, the overlapping with AIH is rare 36 .
An AIH-like entity linked to anti-TNF treatment has recently been described in case reports. 40 Though these result in a significant liver injury, the pathogenesis remains clear 41 . Liver biopsy appears useful, however the differentiation between drug-induced liver injury is not an easy task.
Interestingly, most cases respond well to corticosteroids 42 .
Autoantibodies
Autoantibodies represent a critical feature of AIH and may guide the diagnosis ( Table 2) . In 2004, the IAIH-G established procedures and reference guidelines for more reliable serum autoantibody testing to overcome the lack of standardization 43 . In addition to serum ANA, anti-SM, and anti-LKM, 44 other autoantibodies should also be sought in suspected cases, including anti-LC1, perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), SLA/LP, and the anti asialoglycoprotein receptor antibodies 45 . Finally, less specific autoantibodies may be detected in a subset of patients, including anticardiolipin, anti-chromatin, anti-dsDNA, rheumatoid factor (RF), anti-histones, anti-Ro/SSA, and anti-cyclic citrullinated peptides (anti-CCP) antibodies. Serum ANA were the first autoantibodies observed in AIH sera over 50 years ago and remain the most sensitive marker of AIH 46 . These most frequently produce a homogeneous or speckled pattern.
However, the test is not specific for AIH, since ANA positivity is not uncommon in viral diseases, other autoimmune liver diseases, as well as in up to 15% of healthy subjects, especially in older age groups 47 . Serum SMA are autoantibodies reacting with different proteins (actin, tubulin, vimentin, desmin, cytokeratins) of the cytoskeletal components (microfilaments, microtubuli, intermediate filaments). Their presence characterizes both autoimmune (AIH-1, coeliac disease) and viral diseases (chronic hepatitis C, infectious mononucleosis). When detected at high titers (>1:80), they are considered a sensitive marker for AIH-1, being found in up to 80% of cases. A recent study showed that anti-SMA-T/G positive subject with normal liver function are at low risk of progression to AIH, while positive SMA and raised ALT (>55IU/L) are at higher risk, though the positive predictive value is only 22% 48 . Serum autoantibodies against LKM-1 are the main serological markers of AIH-2, recognizing the proximal renal tubule and hepatocellular cytoplasm.
Serum anti-SLA/LP antibodies are occasionally found in AIH patients who are negative for ANA, SMA, or anti-LKM and are cumulatively detected in 10-30% of cases of AIH-1 and -2. Anti-SLA/LP antibodies are detectable by radioimmunoassay and enzyme-linked immunosorbent assay (ELISA) but not by immunofluorescence and are directed against different epitopes of a UGA tRNA suppressor. Anti-LC1 antibodies are detected by indirect immunofluorescence in sera from up to 50% of patients with type 2 AIH and less frequently in type 1 AIH or chronic hepatitis C.
Importantly, however, anti-LC1 are the only detectable markers in 10% of AIH cases. Interestingly, serum anti-LC1 antibodies correlate with AIH severity and progression. Antibodies to the asialoglycoprotein receptor are observed in up to 90% of patients with AIH and often coexist with other autoantibodies, though they lack specificity for the disease. Similar to anti-LC1, however, anti-asialoglycoprotein titers are associated with a more florid inflammatory disease activity and may allow monitoring of treatment response.
With regard to non-specific antibodies, anti-CCP can be found in 9% of AIH sera, and their detection is independent of concurrent RA but may distinguish early stage RA from nonspecific arthralgia 39 . Moreover, it has been reported than anti-CCP positive subjects are at higher risk of cirrhosis at diagnosis and die more frequently from hepatic failure 21 . Anti-cardiolipin antibodies occur in nearly 40% of AIH, which is more frequently than hepatitis C (20%) and B (14%)
infections. The presence of anti-cardiolipin IgG/IgM is associated with cirrhosis and inflammatory activity 49 , with the IgM subtype being more frequent in AIH than PBC 50 . Further, pANCA can be detected by indirect immunofluorescence in sera from patients with AIH-1, but also in a subgroup of patients with PSC or chronic viral hepatitis. Antibodies to histones are present in 35% of ANApositive patients with autoimmune hepatitis, while anti-dsDNA are detected in 23-34% cases, depending on the nature of the assay and substrate used for their detection 51 . Patients with antihistones are not distinguished by the severity of their disease 52 , while anti-dsDNA positive subjects do not respond or respond less to corticosteroid treatment 53 .
Therapy
In contrast to PBC and PSC, immunosuppressants represent the treatment of choice for AIH, based on the good bio-chemical and histologic response, and survival ( Table 4) 43, 54 . Glucocorticoids--in particular prednisone--in monotherapy or in combination with azathioprine are the first-line treatment. These induce remission (i.e. normal ALT and IgG) in over 80% of the patients, regardless of the presence of cirrhosis 31 . Once achieved, remission can be maintained with azathioprine alone after steroid tapering. The dosage of azathioprine is typically low compared to rheumatic diseases, usually requiring only 50 mg/day and never exceeding 150 mg/day 18 . Relapses following steroid discontinuation are common, since only 20% of patients remain in sustained remission. It should be noted, however, that subgroups of patients manifest disease progression (approximately 10%) or are intolerant to standard therapy (13%). In such patients, other drugs have been anecdotally tried, including methotrexate 55 , cyclophosphamide, tacrolimus, ursodeoxycholic acid, cyclosporine and mycophenolate mofetil, the latter two constituting the most frequently reported alternatives 18, 56 . Biologic therapies commonly used in rheumatology are of particular interest, as pro-inflammatory cytokines, i.e. tumor necrosis factor (TNF)-alpha, are involved in AIH pathogenesis 18 . Infliximab has been used in refractory cases of AIH with reduction of aminotransferases and IgG levels 57 . Rituximab has been tried in a few refractory AIH cases, resulting in improved liver enzymes and IgG, no significant side effects, and a reduction in prednisolone dose for some patients 58 . Future developments may include regulatory T cell therapy, which could allow the avoidance of prolonged often life-long global immunosuppression in patients with AIH 59 . Liver transplantation is the most definitive treatment for AIH patients presenting with acute liver failure or end-stage chronic liver disease and for those with HCC that meet the transplant criteria. Although liver transplantation for these patients is very successful, AIH may recur after transplant. AIH patients undergoing liver transplant have overall 5-and 10-year survival rates of 90% and 75%, respectively, although infectious complications and disease recurrence are common [60] [61] [62] [63] .
Primary biliary cholangitis
PBC is a chronic cholestatic disease characterized by high-titer serum anti-mitochondrial antibodies (AMA) in nearly 100% of patients when sensitive techniques are used. 64 It results in autoimmunemediated destruction of the small and medium-sized intrahepatic bile ducts 17, 65 . PBC prevalence varies substantially according to geography; the highest rates appear in the northern US with a point prevalence of 402 per million in Minnesota 66 . Similar to other autoimmune diseases, PBC most commonly affects women, with a 1:9 male:female ratio 17 , and the average age at PBC diagnosis is within the 5th and 6th decades of life 17 .
Recently, PBC nomenclature has shifted from the term "cirrhosis" to "cholangitis", which is more precise and removes the stigma associated with cirrhosis. This change reflects the dramatically improved PBC prognosis and treatment, since nowadays, two out of three patients diagnosed with PBC and treated with ursodeoxycholic acid (UDCA) have an expected survival comparable to the general population and only a minority will ever develop cirrhosis 67, 68 .
Clinical features
Early PBC symptoms are classically described as fatigue and pruritus while physical findings may include skin hyperpigmentation, hepatosplenomegaly, and (rarely) xanthelasmas. Fatigue and pruritus are nonspecific symptoms present in 70% of PBC patients. Conversely, end-stage symptoms are secondary to the complications of liver cirrhosis, including ascites, jaundice, hepatic encephalopathy, and upper digestive bleeding. Portal hypertension is frequently found in patients with PBC and, importantly, does not imply the presence of liver cirrhosis. Metabolic bone disease is elevated in PBC compared to sex-and age-matched healthy individuals (see below). Similar to other types of cirrhosis, end-stage PBC can be complicated by the occurrence of HCC. The progression of PBC varies widely, and the factors influencing the severity and progression of the disease are largely unknown. The presence of symptoms at presentation, however, are a major factor determining PBC survival rates; asymptomatic PBC produces 10-year survival rates shorter than the general population, but symptomatic PBC produces even shorter survival rates 68 .
The diagnosis of PBC is generally based on the presence of two of the following three criteria: (1) biochemical evidence of cholestasis with elevation of alkaline phosphatase activity over six months;
(2) presence of serum AMA at significant titers; and (3) histological non-suppurative cholangitis and destruction of small or medium-sized bile ducts on biopsy specimen. The differential diagnosis includes a cholestatic drug reaction, biliary obstruction, sarcoidosis, AIH and PSC (Table 4) 69 .
Association with rheumatic diseases
PBC is commonly associated with a number of extrahepatic autoimmune conditions. A recent monocentric study identified a co-occurrence in more than 60% of patients, with the most common being SjS in 30% of patients, followed by Raynaud's phenomenon in 18%, and Hashimoto's thyroiditis. PBC and SSc are associated in 6% of cases 70 , while a higher frequency of RA (up to 10%) has been reported since the 1970s 71 , 72 . PBC has also been reported in the presence of HLA-B27 enthesopathy. 73 Interestingly, 5% of PBC cases also suffer from autoimmune cutaneous conditions 74 , 75 . Surprisingly, when extrahepatic autoimmune diseases co-occur with PBC, the cases tend to be less severe; severe SjS occurs in 10.5% of PBC cases, and the PBC disease is usually milder and at early stage (stage I-II at liver histology) in the presence of SjS 76, 77 . The same observation has been made with PBC and SSc. PBC most commonly associates with limited cutaneous SSc (lSSc), and patients with PBC/SSc overlap have a slower rate of liver-disease progression compared to matched patients with PBC alone 78 . Female sex is the only significant risk factor for at having a second autoimmune condition 70 , while neither autoantibodies nor liver histology differ.
Autoantibodies
PBC is characterized serologically by the presence of AMA, which are highly specific for the disease. These antibodies are found in 90-95% of PBC patients compared with less than 1% of healthy subjects 79 . Similar to other autoimmune diseases, AMA positivity arises years before the development of PBC 9 , and AMA are included in the internationally-accepted criteria for PBC diagnosis ( Table 5) 80 . AMA are directed against components of the 2-oxoacid dehydrogenase (2-OADC) family of enzymes within the mitochondrial respiratory chain, most frequently the E2 and E3-binding protein (E3BP) components of the pyruvate dehydrogenase complex and the E2 components of the 2-oxo glutarate dehydrogenase and branched-chain 2-oxo acid dehydrogenase complexes 81 . All three antigen epitopes contain the motif DKA, with lipoic acid covalently bound to the lysine (K) residue 78 . ANA have been identified in 52% of patients, with the most specific patterns being "nuclear-rim" and "multiple nuclear dots", produced by antibodies directed against the nuclear membrane gp120 and nucleoporin 62, and the nuclear body sp100, sp140 and promyeolocytic leukaemia proteins, respectively ( Table 1) [82] [83] [84] [85] . ANA-positive patients are more frequently AMA-negative, possibly because of the lack of a masking effect of these latter antibodies in such sera. While ACA are most specific for lSSc, found in up to 90% of cases, they are also detectable in 9-30% of PBC patients. This prevalence exceeds that of the PBC/SSc overlap syndrome 86, 87 . ACA recognize six centromere polypeptides belonging to the kinetochore proteins:
CENP-A, CENP-B, CENP-C, CENP-D, CENP-E, CENP-F, with the major autoantigen being CENP-B. The clinical significance of ACA in PBC remains ill-defined as it is unclear whether ACA represents a pre-clinical marker of lSSc or a subclinical form of the disease. Moreover, ACA could simply represent an epiphenomenon of the immune dysregulation present in PBC 78 . Some have posited that since ACA can predict the development of SSc and since early SSc may be frequent in PBC, these may facilitate timely detection of complications, preventing disability and reducing the probability of liver transplantation 88 , 78 . In any case, patients with PBC and positive ACA with SSc-related symptoms should be assessed for organ involvement, and in particular, assessment of pulmonary arterial hypertension by echocardiography should be considered in all PBC/SSc patients. Unfortunately, currently utilized tools to predict this pulmonary arterial hypertension (e.g. the DETECT score) have not been evaluated in PBC patients 89 . Furthermore, while PBC/SSc seems to have a milder disease course, ACA positive PBC patients have a more severe bile duct injury and more frequently portal hypertension 78 . With regard to other autoantibodies 90 , anti-ENA are positive in up to 40% of PBC cases, regardless of the extrahepatic autoimmunity 70 , with no effect on disease severity or progression. Anti-Ro/SSA are found in PBC/SjS overlap in 10% of cases 90 , anti-dsDNA in 22% of PBC patients 90 while anti-cardiolipin IgM positive in 75% of PBC, advanced stage disease 91 .
Therapy
PBC treatment is currently based on UDCA, which is the only approved drug. Its mechanism of action is incompletely understood and possibly dependent on the various phases of the disease 5, 92 .
During the early disease, short-term glucocorticoids might be effective, however, prolonged use raises safety concerns. Budesonide, due to its high first-pass metabolism, has minimum systemic adverse effects, and, at 6-9 mg daily, has been demonstrated to be superior to UDCA both in terms of histology and biochemical markers. Other immunosuppressants, such as methotrexate and azathioprine, have also been suggested and there is evidence supporting the use of the latter in PBC with autoimmune hepatitis overlap syndrome 93 . The use of biologics targeting TNF-alpha has been reported in few cases of overlap syndromes with rheumatic diseases 94, 95 . In the last years, improved understanding of PBC pathogenesis has led to the testing of new targeted therapies, especially those modulating the IL-17/23 axis. Ustekinumab, a monoclonal antibody against the p40 subunit, however, demonstrated only a very modest decrease in ALP after 28 weeks of therapy, and was otherwise deemed ineffective 19 . Other therapies targeting T cells 96 , including those that bind CTLA-4 (abatacept) or antagonize CD40 (FFP104) are under investigation 69, 97, 98 . Of note, the use CTLA-4 Ig in PBC murine model prevents cholangitis manifestations (AMA production, intrahepatic T-cell infiltrates, and bile duct damage) and reduces disease severity in established murine disease 99 . When the disease has already progressed and bile is accumulated, obeticholic acid (OCA)--an analogue of chenodeoxycholic acid with a much higher affinity to the farnesoid X receptor (FXR)--has been shown to decrease bile synthesis, promote secretion, and induce liver regeneration in animal models. Furthermore, a recent Phase III trial of OCA administered with UDCA or as monotherapy for 12 months demonstrated decreases in alkaline phosphatase and total bilirubin levels compared with placebo 97 . Ultimately, UDCA represents the cornerstone therapy of PBC and dosages ranging from 13 to 15 mg/kg lead to optimum bile enrichment, with 50% of patients normalizing their alkaline phosphatase. Other immunosuppressive treatments should be started only in combination with UDCA.
Liver transplantation may be necessary for end-stage PBC, with survival rates of 92% and 85% at 1 and 5 years after transplant, respectively. Recurrence is common seems to be influenced by immunosuppressives, while the use of UDCA for recurrence is safe and recommended.
Primary sclerosing cholangitis
PSC is a progressive cholestatic liver disease of unknown etiology presenting with chronic inflammatory features of the bile ducts of any size and associated with significant morbidity and mortality 100, 101 . In contrast to PBC, PSC can affect all tracts of the biliary tree, including the extrahepatic bile ducts visible with imaging modalities and the small bile ducts observed via liver histology. The prevalence of PSC is approximately 10/100000 in Northern Europe 28 and in the US, while it is far less common in Southern Europe and Asia; recent data from the Olmstead County, Minnesota, report a prevalence of 20.9 per 100 000 men and 6.3 per 100 000 women 102 . Different from PBC and AIH, PSC affects more frequently men, with a 2:1 male:female ratio 102 .
Clinical features
PSC symptoms are generally nonspecific and include abdominal pain, jaundice, and fever in the case of bacterial cholangitis, while at more advanced stages, symptoms include those typical of decompensated cirrhosis or neoplasia. Commonly, PSC is complicated by episodic bacterial cholangitis precipitated by biliary strictures. Discrete subgroups of patients manifest the "smallduct" or overlap syndrome variants. Due to the nonspecific symptoms, PSC is usually diagnosed during routine blood tests in otherwise healthy individuals or patients with IBD 103 . Testing characteristically reveals a biochemical cholestatic pattern, as represented by elevated serum alkaline phosphatase and γ-glutamyltransferase, though tests of liver function are normal until late stages. Imaging (particularly bile duct MRI or endoscopy) represents a useful diagnostic tool, as it may identify the classic strictured and dilated intrahepatic or extrahepatic bile ducts 102 . Performing a liver biopsy is generally not necessary for the diagnosis of PSC, except in the case of small-duct PSC which requires histologic examination. The natural history of this form is relatively benign and only a minority (12%) of patients progress to classical PSC. The median timespan from diagnosis to liver-related death or liver transplantation is 18 years, and the prognosis is influenced by the onset of cholangiocarcinoma (CCA). CCA is more common with chronic biliary inflammation and difficult to distinguish from stricturing PSC 101 .
Association with rheumatic diseases
The association of PSC with IBD is well established. Nearly 70% of PSC cases also demonstrate findings of IBD 104 , frequently in mild asymptomatic forms, while 7% of IBD patients have PSC 105 . Liver abnormalities are more frequently found in psoriatic patients, and this is typically attributed to non-alcoholic or alcoholic fatty liver 106 . However, in generalized pustular psoriasis, a less common form of psoriasis associated with extra-cutaneous manifestations, evidence for biliary involvement has been suggested, and neutrophilic cholangitis has been observed on liver biopsy, while magnetic resonance cholangiopancreatography showed features similar to those observed in PSC 107 .
Autoantibodies
In contrast to other autoimmune liver diseases, autoantibodies are of limited use in the diagnosis of PSC due to low sensitivity and specificity; only a limited percentage of patients (33%) have positive p-ANCA 108,109 , for example. Only for PSC forms overlapping with AIH is serum ANA typically detected.
Therapy
The treatment of PSC is largely an unmet need and currently includes medical and endoscopic measures, short of liver transplantation 110, 111 . UDCA has been investigated in several clinical trials, with conflicting results. Overall, the available evidence suggests that UDCA does not produce a substantial change in the course of PSC, despite remaining the most prescribed drug. However, it appears that high-dose UDCA (20 mg/kg/day) or norUDCA, a side chain-shortened homologue of UDCA, may reduce reduced biochemical indices of cholestasis 112 , the rate of progression, and might prevent the development of colon cancer (particularly in patients with UC/PSC overlap).
Based on these inconclusive data, the use of UCDA in PSC varies widely, reflecting regional practice trends rather than science. Endoscopic interventions are indicated to treat complicated PSC through the dilation of short-and long-segment stenosis of the common bile duct and short-segment stenosis of the hepatic ducts near to the bifurcation. The treatment can be repeated over time once restenosis ensues and resulting survival rates are higher compared to patients not treated endoscopically. Biologics, mainly anti-TNF, have been used in PSC with concomitant IBD or rheumatic diseases with improvement in laboratory measurements 113, 114 but patients with PSC are generally excluded from IBD clinical trials, thus preventing firm conclusions regarding efficacy. 
Commentato [CS2]: I would maintain this as it is a less known secret for PSC people
Autoimmune liver diseases, similarly to rheumatic disease, may overlap and present with both hepatocellular and cholangiocellular patterns according to biochemical, histologic, and imagingbased analysis. When left without treatment, these patients show a more progressive course toward liver cirrhosis and failure. AIH-PBC overlap syndrome is found in 10% of adults with AIH whereas AIH-PSC overlap syndromes affects 6-8% of children, adolescents, and young adults with AIH; PBC-PSC overlap syndrome is exceptionally rare ( Table 6 
Osteometabolic consequences of chronic autoimmune liver disease.
Advancements in the management of autoimmune liver diseases and cirrhosis complications have increased survival rates. However, longer survival rates, compounded by an aging population, have increased the risk of complications such as osteoporosis. Osteoporosis is associated with increased risk of fracture, which is two-fold higher in cirrhotic patients regardless of the liver disease etiology, and persists for years after liver transplantation [116] [117] [118] [119] . Moreover, patients receiving glucocorticoids for AIH suffer an additional decrease in their bone mass.
According to the WHO definition, osteoporosis is diagnosed when bone density is less than 2.5 standard deviations below the peak value obtained from normal adults and adjusted for gender (T score) 120 . This definition is limited insofar as the threshold was established from studies of postmenopausal Caucasian women, rather than for patients with liver diseases. 117 Therefore, some authors favor the term hepatic osteodystrophy, though this term also includes osteomalacia 121 .
The mechanisms of cirrhosis-related osteoporosis are not fully understood, but it is generally recognized that the association between liver and bone diseases occurs due to an imbalance of bone turnover, which depends on the osteoblastic and osteoclastic activity 122 . In PBC, while the exact mechanism is also not completely understood, there is evidence that hormone balance, genetics, and cholestasis may contribute to determine bone structure and density changes. There has been conflicting evidence as to whether PBC-related osteoporosis results from diminished bone formation, which is a low-turnover state, or from increased bone resorption, which is a highturnover state. However, recent data suggest that bone formation is the culprit. Cirrhosis is associated with the reduction of specific growth factors, such as insulin-like growth factor 1, which impairs osteoblast function and bone formation; severe cholestasis can allow build-up of lithocholic acid, which inhibits osteoblast activity and can interfere with genetic regulation of bone formation 23 .
The prevalence of osteoporosis in cirrhotic patients ranges from 12 to 70% according to the diagnostic modality and the liver disease etiology, with cholestatic diseases having a higher prevalence (20-44%, even without an established diagnosis of cirrhosis). Moreover, fracture rates are increased in cholestatic diseases, varying from 13 to 22% according to the degree of liver function 120 .
Screening for osteoporosis is an important part of liver diseases management, and the guidelines indicate that patients with cirrhosis and PBC should be screened by an initial dual-energy X-ray absorptiometry (DXA) exam 121 . If initial results are normal, the DXA should be repeated every 1 to 3 years to assess significant bone loss, depending on the presence of additional risk factors (BMI less than 19 kg/m 2 , heavy alcohol use, tobacco use, early menopause [<age 45 years], glucocorticoid use greater than 3 months, or family history of bone fragility fractures). 121 In addition, BMD should be measured prior to liver transplantation. for liver disease patients. Calcitriol is usually prescribed as a daily oral dose of 800 IU but can also be taken at a weekly dose of 5000 IU 120 . In PBC, calcium and vitamin D supplementation alone was inferior to hormonal replacement therapy in improving BMD. 124, 125 However, testing for vitamin D deficiency in cholestatic patients is useful to allow for appropriate supplementation, particularly in those taking cholestyramine, since this impairs vitamin D absorption 116 .
Bisphosphonates represent the treatment of choice for osteoporosis in cirrhotic patients, because they attach to the bone surface and prevent resorption. 126 . The threshold of intervention in patients with liver disease, however, may be lower than in the general population, since in PBC T-scores below -1.5 are associated with a significant risk for vertebral fractures 127 . A recent randomized controlled trial for osteoporosis therapy in PBC patients showed that both monthly ibandronic acid and weekly alendronic acid improve bone mass and are comparable in safety, although adherence is higher with the monthly regimen 128 . Moreover, bisphosphonates and teriparatide reduce the risk of vertebral fractures in chronically glucocorticoid-treated patients 129 , 130 . Hormone replacement therapy does not show any osteoporosis benefit for PBC patients, but its use is no longer contraindicated in chronic cholestasis 131 . Ultimately, treating PBC with UDCA may have beneficial effects also on the bone, since UDCA may increase osteoblast differentiation and jaundiced patients on osteoblastic cells 132 .
Concluding remarks.
The coexistence of liver and rheumatic diseases represents an ideal example of the need for a interdisciplinary approach to individualize treatments. Indeed, patients with autoimmune liver diseases may be undertreated with anti-rheumatic drugs for liver safety concerns (as in the case of methotrexate), while liver test changes may raise unnecessary concerns. Furthermore, new biologics may be beneficial for more than one condition, though insufficient data exist from the hepatology perspective. Lastly, the rapid deterioration of bone health associated with chronic liver diseases is an obvious area of collaboration between gastroentology and rheumatology. With the current focus on personalized medicine, the coexistence of liver autoimmunity and rheumatic disease is an ideal area to develop and investigate the benefits of shared clinical practice. antimitochondrial antibodies. 
